PTC Therapeutics Inc. (PTCT) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (41% profit margin, 85% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
PTC Therapeutics Inc. (PTCT) surged +2.29% to $64.46 as options desks priced 58% call premium vs. 42% put protection around the $63 max-pain magnet. High-quality cash engine (41% profit margin, 85% return on capital) with steady institutional support.
PTC Therapeutics just reported Q3 2026 and the headline is simple. Product revenue is now anchored by Sephience and Q3 brought in US$358 million of total revenue, yet the stock dropped about 7% on the day to roughly US$6
PTC Therapeutics (PTCT) is back in focus after its third quarter, when revenue of US$357.81 million topped analyst forecasts and management lifted full year sales guidance for 2026. Despite the upbeat third quarter and h
Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123. Since the thesis was published on August 30th, RARE shares have pulled back as a k
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units
TD Cowen analyst Joseph Thome maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and raises the price target from $90 to $95.
Sephience revenue hit $182 million as the company raised full-year guidance.
For questions about this article or underlying research, email help@trefis.com.
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and raises the price target from $75 to $77.
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.
Moby summary of PTC Therapeutics, Inc.'s Q3 2026 earnings call
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +114.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PTCT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PTCT. Explore sector supply chains on /butterfly.
Why PTCT Stock surged +2.29% Today — RQD Quant Desk Flash. High-quality cash engine (41% profit margin, 85% return on capital) with steady institutional support.